Pulse Angels

Every investment passes through Mohan Cashyap, the Founder and Managing Partner, who spent 34 years at GSK and leads clinical validation and fundraising preparation. He is joined by Simran Cashyap, who leads technology and commercial due diligence. Deals are presented to the full syndicate for individual decision-making; there is no central investment committee that commits capital on behalf of members.

The syndicate screens more than 200 deals annually, with inbound opportunities originating primarily through member referrals. A representative case study published by the firm describes an investment that arrived via a syndicate-member introduction, was confirmed as a MedTech fit, and then passed through clinical-evidence review, regulatory-route confirmation, and unit-economics stress-testing before a briefing note was issued to members.

Pulse Angels is a deal-by-deal angel syndicate, not a commingled venture fund. Members receive detailed briefing packs for each opportunity and decide individually whether to participate. This structure gives investors direct ownership in portfolio companies and allows them to claim EIS or SEIS tax relief when applicable.

Pulse Angels invests exclusively through direct syndicate investments into individual companies. There is no public record of the syndicate making LP commitments into third-party venture funds, pooling member capital into a blind pool, or operating a fund-of-funds program.

The syndicate targets pre-seed and seed stages. Its check size is £50,000 to £500,000, and it looks for companies where domain expertise is as important as the technology — typically with a clear clinical problem, evidence of demand, a credible team, a realistic regulatory pathway, and unit economics that work.

Portfolio companies operating in Scotland or Wales can access £350,000 to £2 million in match funding through Pulse Angels' co-investment partnerships with Scottish Enterprise and the Development Bank of Wales. The syndicate helps qualifying companies trigger this funding after the Pulse Angels round closes, effectively multiplying the capital available without increasing the syndicate's check size.

The syndicate regularly co-invests with regional development bodies and partner networks, but there is no public disclosure of institutional venture funds co-investing alongside Pulse Angels rounds. The firm's published materials emphasize co-investment with government-backed entities and specialist regulatory and technical partners rather than with GPs.